The Latin American Society of Interventional Cardiology (SOLACI) promotes the study of medicine and the implementation of best practices in cardiovascular care in the field of cardiac catheterization, and organizes major scientific events on interventional cardiology in Latin America and the Caribbean. We organize Regional Sessions to promote interventional cardiology in each country with the<a href="https://solaci.org/en/2015/10/28/about-the-solaci-sessions/" title="Read more" >...</a>
WOEST: Randomized trial that compared dual therapy versus triple therapy on anticoagulated patients.
A multicenter randomized study, (n = 573), that evaluated the role of aspirin in anticoagulated patients undergoing angioplasty. The primary endpoint was the rate of total bleeding, (TIMI), at 12 months follow-up. The administration of a dual therapy, (warfarin + clopidogrel), showed a significant reduction compared with the triple therapy, (19.5% vs. 44.9%, P <0.001).<a href="https://solaci.org/en/2015/06/24/woest-randomized-trial-that-compared-dual-therapy-versus-triple-therapy-on-anticoagulated-patients/" title="Read more" >...</a>
TASTE: Thrombus aspiration in primary angioplasty failed to show benefits at 30 days
The clinical benefit of thrombus aspiration during angioplasty in patients with ST-segment elevation myocardial infarction is uncertain. The purpose of this work was to test if thrombus aspiration reduces mortality. This was a multicenter, prospective, randomized and controlled study that included patients with ST-segment elevation myocardial infarction within 24 hours of evolution. The catheters used<a href="https://solaci.org/en/2015/06/24/taste-thrombus-aspiration-in-primary-angioplasty-failed-to-show-benefits-at-30-days/" title="Read more" >...</a>
2nd-generation drug-eluting stents, results for “real” patients at two years
Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press. In recent years there have been new drug-eluting<a href="https://solaci.org/en/2015/06/02/2nd-generation-drug-eluting-stents-results-for-real-patients-at-two-years/" title="Read more" >...</a>
SOLACI -SIAC collaboration agreement
As the President of the Interamerican Society of Cardiology, (SIAC), I am honored to sign this important agreement with SOLACI. Our societies have an enormous responsibility to improve cardiology in Latin America and we know that this is not an easy task: we are nations with different backgrounds, sometimes different languages and at different stages<a href="https://solaci.org/en/2015/06/02/solaci-siac-collaboration-agreement/" title="Read more" >...</a>
SOLACI relaunches its SOLidario program in Colombia
The Latin American Society of Interventional Cardiology successfully relaunched its SOLidario program, practicing the implantation of an aortic valve catheter (TAVI) in the Instituto de Angiografía de Occidente at Cali. It was during the XXIV SOLACI Conference edition held on October 30 and 31 in Colombia. SOLACI understands the need to develop a social<a href="https://solaci.org/en/2015/06/02/solaci-relaunches-its-solidario-program-in-colombia/" title="Read more" >...</a>
Letter from the President 2013-2015
By Jamil Abdalla SaadSOLACI President. Dear friends and colleagues, With great honor, we assume the SOLACI presidency for 2013-2015. The commitment to exercising command on a continental society, succeeding three illustrious predecessors, is always a challenge and this time is renewed in observing Brazil. The governing board is completed by Ricardo Lluberas MD (Uruguay<a href="https://solaci.org/en/2015/06/02/letter-from-the-president-2013-2015/" title="Read more" >...</a>
SOLACI presents the Brazilian Magazine of Interventional Cardiology
Ir a la REVISTA Dr. Oscar Mendiz | President of SOLACI We are very pleased to announce one further step in the strong cooperation between SOLACI and SBHCI: the translation into Spanish of the Brazilian Magazine of Interventional Cardiology, and the chance to send papers in this language. This is a significant milestone that enables an<a href="https://solaci.org/en/2015/06/02/solaci-presents-the-brazilian-magazine-of-interventional-cardiology/" title="Read more" >...</a>
In a decade, minimally invasive procedures will replace open-heart surgery entirely
Minimally invasive interventions allow us to respond to any complications related to the heart, so it is expected to decrease open-heart surgery dramatically; in a decade, minimally invasive procedures definitely replace conventional surgery. This was highlighted on Wednesday during the XXV Meeting of the Cardiac Catheterization and Interventional Cardiology of the Spanish Society of Cardiology<a href="https://solaci.org/en/2015/06/01/in-a-decade-minimally-invasive-procedures-will-replace-open-heart-surgery-entirely/" title="Read more" >...</a>
Net clinical benefit of bivalirudin in STEMI patients
Original title: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials. Reference: Stone GW et al. J Am CollCardiol. 2015 Jan 6;65(1):27-38. The HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) that included 3602 STEMI patients undergoing<a href="https://solaci.org/en/2015/01/29/net-clinical-benefit-of-bivalirudin-in-stemi-patients/" title="Read more" >...</a>